271 related articles for article (PubMed ID: 34285332)
21. Analysis of
Okamura R; Boichard A; Kato S; Sicklick JK; Bazhenova L; Kurzrock R
JCO Precis Oncol; 2018; 2018():. PubMed ID: 30637364
[TBL] [Abstract][Full Text] [Related]
22. NTRK fusion analysis reveals enrichment in Middle Eastern BRAF wild-type PTC.
Kong Y; Bu R; Parvathareddy SK; Siraj AK; Siraj N; Al-Sobhi SS; Al-Dayel F; Al-Kuraya KS
Eur J Endocrinol; 2021 Apr; 184(4):503-511. PubMed ID: 33524004
[TBL] [Abstract][Full Text] [Related]
23. NTRK fusions are extremely rare in bone tumours.
Lam SW; Briaire-de Bruijn IH; van Wezel T; Cleven AHG; Hogendoorn PCW; Cleton-Jansen AM; Bovée JVMG
Histopathology; 2021 Nov; 79(5):880-885. PubMed ID: 34148257
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of NTRK immunohistochemistry as a screening method for NTRK gene fusion detection in non-small cell lung cancer.
Elfving H; Broström E; Moens LNJ; Almlöf J; Cerjan D; Lauter G; Nord H; Mattsson JSM; Ullenhag GJ; Strell C; Backman M; La Fleur L; Brunnström H; Botling J; Micke P
Lung Cancer; 2021 Jan; 151():53-59. PubMed ID: 33310622
[TBL] [Abstract][Full Text] [Related]
25. NTRK gene fusions in melanoma: detection, prevalence and potential therapeutic implications.
Forschner A; Forchhammer S; Bonzheim I
J Dtsch Dermatol Ges; 2020 Dec; 18(12):1387-1392. PubMed ID: 32656925
[TBL] [Abstract][Full Text] [Related]
26. Identifying patients with NTRK fusion cancer.
Solomon JP; Benayed R; Hechtman JF; Ladanyi M
Ann Oncol; 2019 Nov; 30 Suppl 8():viii16-viii22. PubMed ID: 32223934
[TBL] [Abstract][Full Text] [Related]
27. Systematic review of NTRK 1/2/3 fusion prevalence pan-cancer and across solid tumours.
O'Haire S; Franchini F; Kang YJ; Steinberg J; Canfell K; Desai J; Fox S; IJzerman M
Sci Rep; 2023 Mar; 13(1):4116. PubMed ID: 36914665
[TBL] [Abstract][Full Text] [Related]
28. NTRK fusion-positive cancers and TRK inhibitor therapy.
Cocco E; Scaltriti M; Drilon A
Nat Rev Clin Oncol; 2018 Dec; 15(12):731-747. PubMed ID: 30333516
[TBL] [Abstract][Full Text] [Related]
29. A systematic review and meta-analysis of neurotrophic tyrosine receptor kinase gene fusion frequencies in solid tumors.
Forsythe A; Zhang W; Phillip Strauss U; Fellous M; Korei M; Keating K
Ther Adv Med Oncol; 2020; 12():1758835920975613. PubMed ID: 33425024
[TBL] [Abstract][Full Text] [Related]
30. Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors.
Konicek BW; Capen AR; Credille KM; Ebert PJ; Falcon BL; Heady GL; Patel BKR; Peek VL; Stephens JR; Stewart JA; Stout SL; Timm DE; Um SL; Willard MD; Wulur IH; Zeng Y; Wang Y; Walgren RA; Betty Yan SC
Oncotarget; 2018 Mar; 9(17):13796-13806. PubMed ID: 29568395
[TBL] [Abstract][Full Text] [Related]
31. Identification of NTRK fusions in pediatric mesenchymal tumors.
Pavlick D; Schrock AB; Malicki D; Stephens PJ; Kuo DJ; Ahn H; Turpin B; Allen JM; Rosenzweig M; Badizadegan K; Ross JS; Miller VA; Wong V; Ali SM
Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28097808
[TBL] [Abstract][Full Text] [Related]
32. Neurotrophic tropomyosin or tyrosine receptor kinase (NTRK) genes.
Chetty R
J Clin Pathol; 2019 Mar; 72(3):187-190. PubMed ID: 30636697
[TBL] [Abstract][Full Text] [Related]
33. Comprehensive genomic profiling identifies novel NTRK fusions in neuroendocrine tumors.
Sigal DS; Bhangoo MS; Hermel JA; Pavlick DC; Frampton G; Miller VA; Ross JS; Ali SM
Oncotarget; 2018 Nov; 9(88):35809-35812. PubMed ID: 30533196
[TBL] [Abstract][Full Text] [Related]
34. Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers.
Boilève A; Verlingue L; Hollebecque A; Boige V; Ducreux M; Malka D
Expert Opin Investig Drugs; 2021 Apr; 30(4):401-409. PubMed ID: 33641556
[No Abstract] [Full Text] [Related]
35. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.
Hechtman JF; Benayed R; Hyman DM; Drilon A; Zehir A; Frosina D; Arcila ME; Dogan S; Klimstra DS; Ladanyi M; Jungbluth AA
Am J Surg Pathol; 2017 Nov; 41(11):1547-1551. PubMed ID: 28719467
[TBL] [Abstract][Full Text] [Related]
36. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
[TBL] [Abstract][Full Text] [Related]
37. A review of NTRK fusions in cancer.
Manea CA; Badiu DC; Ploscaru IC; Zgura A; Bacinschi X; Smarandache CG; Serban D; Popescu CG; Grigorean VT; Botnarciuc V
Ann Med Surg (Lond); 2022 Jul; 79():103893. PubMed ID: 35860155
[TBL] [Abstract][Full Text] [Related]
38. Indirect Treatment Comparison of Larotrectinib versus Entrectinib in Treating Patients with TRK Gene Fusion Cancers.
Garcia-Foncillas J; Bokemeyer C; Italiano A; Keating K; Paracha N; Fellous M; Marian M; Fillbrunn M; Gao W; Ayyagari R; Lassen U
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406565
[TBL] [Abstract][Full Text] [Related]
39. Pursuit of Gene Fusions in Daily Practice: Evidence from Real-World Data in Wild-Type and Microsatellite Instable Patients.
Berrino E; Bragoni A; Annaratone L; Fenocchio E; Carnevale-Schianca F; Garetto L; Aglietta M; Sarotto I; Casorzo L; Venesio T; Sapino A; Marchiò C
Cancers (Basel); 2021 Jul; 13(13):. PubMed ID: 34282766
[TBL] [Abstract][Full Text] [Related]
40. Systematic population-based identification of NTRK and RET fusion-positive thyroid cancers.
Eszlinger M; Stewardson P; McIntyre JB; Box A; Khalil M; Hyrcza M; Koro K; Ruether D; Wu J; Paschke R
Eur Thyroid J; 2022 Jan; 11(1):. PubMed ID: 34981751
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]